Common growth equity
For investors taking long-term participation in enterprise and balance-sheet growth.
Equity and strategic capital for lenders, wealth platforms, asset managers, insurance and specialist financial-services businesses seeking USD 5m or more.

Capital must be sized against growth, balance-sheet needs, loss absorption, operating leverage and the time required for new assets or customers to season.
We begin with the commercial objective, the amount and timing of capital, the evidence available and the authority to run the transaction. The resulting route can then be tested against realistic investor, lender or buyer criteria.
The route is selected after reviewing cash flows, control, security, dilution, timing and counterparty appetite.
For investors taking long-term participation in enterprise and balance-sheet growth.
For capital paired with funding, distribution or product collaboration.
For negotiated return, conversion or downside-protection features tied to milestones.
The sequence is adapted to transaction readiness, confidentiality and the selected capital route.
Public mandate summaries are current at the website build date. Detailed information is available following counterparty qualification.
Specialist lenders, wealth and asset-management platforms, insurance businesses and financial infrastructure companies may be considered for mandates from USD 5m upwards.
The review links origination growth, funding, capital, liquidity, credit performance, operating cost and profitability under base and downside cases.
Yes. A strategic transaction may combine equity with warehouse funding, distribution or product collaboration where the commercial terms are aligned.
Historical financials, portfolio and vintage performance, funding profile, customer economics, growth plan, ownership and governance information are commonly required.
Share your company, transaction type and approximate ticket size. A partner will review the fit for a USD 5m+ mandate.